Transcript Private Sector Perspective - About Trade, TRIPS and Access to

Pharmaceutical Manufacturers
Association PMA
Status of National Production Capacity of
Generic Medicines – Private Sector
Perspective
Emmanuel Mujuru, PMA Chairperson
PMA Membership
• Pharmaceutical Manufacturing Companies
• Advocacy – Enabling Economic, Regulatory & Policy
Environment
• Nine Companies Namely
1.
2.
3.
4.
5.
6.
7.
8.
9.
CAPS
Datlabs
Graniteside
Gulf Drug Company
Ecomed
Pharmanova
Plus Five Pharmaceuticals
Varichem
Zimpharm
PMA
PMA OBJECTIVES
Create a vibrant, globally competitive and
self-sustaining pharmaceutical
manufacturing industry in Zimbabwe
Self-sufficiency and reliability in the local
production of affordable efficacious and
quality essential generic medicines
Promote access to safe, quality,
efficacious medicines in Zimbabwe and
region
Contribute positively to the economic and
scientific development of the country
3
COMMON ASPIRATIONS
Access to medicines
• Quality
• Safety
• Efficacy
• Affordability
• Availability
The eye sees not itself but by reflection –
William Shakespeare
4
State of The Industry
• Serious viability problems
• Low capacity utilisation < 40%
• ≤45% of Essential Drugs EDLIZ down from
>75%
• <15% Specialist Drugs SEDLIZ
• Lack of investment in the past 10yrs
• Old facilities in need of urgent upgrade
• Product Development
• Deindustrialisation
• Competitiveness
5
Challenges Facing The Industry
• Duties and VAT on raw materials and packaging
• Collapse of public sector market ≤22% essential drug
availability of which > 90% donations
• Policy incoherencies/Disharmony
• Procurement policies
• Funding
• Donations
• Non-Tariff Barriers e.g. exports to South Africa
• Corruption
• Regulatory and registration policies
• Counterfeits
• Cheaper Imports - India
Public Health
Employment, Economic
and Scientific
Development
Patients
Price, Quality, Efficacy,
Availability
Balancing Interests of Public Health
Policy & Industrial Development Policy
Industry
Industrial
Development
Moving together
Regulators
Manufacturers
Policy
Regulations
Rights issues
Consumers
Procurement agencies
Health Facilities
CASE STUDIES
• GHANA MODEL - $300Mln Market ; 32
Manufacturers; 44 restricted list; raw
materials exempted from duty and VAT
• Tunisia – Importation banned as soon as
product is locally produced >80% local
• SA – 75% of public sector requirements
should be sourced locally
• India & China – benefit from a number of
policy measures : protection from tariff
regimes and procurement preferences as
well as direct support : interest subsidies,
export credits; cheap utilities; working
capital credits and tax holidays
9
RALLYING POINTS
• Levelling of playing field – remove VAT and
duty on pharma-raw materials
• Import restriction of commonly produced
drugs – 40 products
• Capacitation of NATPHARM
• Local preference on public tenders e.g.
Natpharm, NAC etc.
• Establishment of local BE Centre
• Fast track preferential registration – MCAZ
• R&D collaborative drug development with
Universities, Traditional Healers etc.
• Domestication of TRIPS flexibilities
• Funding
• Export competitiveness - $20bln African
Market growing >10% annually
10
Our Shared Vision
• Production of affordable, safe, efficacious and
quality essential medicines
• Universal access to essential medicines
• Positive public health outcomes
• Employment, Economic and Scientific development
THANK YOU